709. Activity of Key β-Lactam Agents Against Gram-Negative Bacilli From ICU Patients with Lower Respiratory Tract Infections, SMART United States 2015–2017

BACKGROUND: Relebactam (REL), formerly MK-7655, is a β-lactamase inhibitor of class A and C β-lactamases that is in clinical development in combination with imipenem (IMI). In this study, we evaluated the activity of IMI/REL against Gram-negative bacilli and resistant phenotypes collected in the Uni...

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle, Kazmierczak, Krystyna, Hoban, Daryl, Hackel, Meredith, Young, Katherine, Motyl, Mary, Sahm, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253199/
http://dx.doi.org/10.1093/ofid/ofy210.716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253199/
http://dx.doi.org/10.1093/ofid/ofy210.716

Ejemplares similares